uniQure (NASDAQ:QURE) Director Sells $53,930.58 in Stock

uniQure N.V. (NASDAQ:QURE) Director Rachelle Suzanne Jacques sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the transaction, the director owned 33,903 shares in the company, valued at approximately $917,415.18. This represents a 5.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

uniQure Price Performance

uniQure stock opened at $27.57 on Monday. The business’s 50-day simple moving average is $22.52 and its 200 day simple moving average is $21.76. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, research analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current year.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp boosted its holdings in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System boosted its holdings in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the last quarter. Finally, FNY Investment Advisers LLC boosted its holdings in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on QURE shares. Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th. Chardan Capital raised their price target on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Finally, Barclays reduced their target price on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.